GC
REGN icon

Gilbert & Cook’s Regeneron Pharmaceuticals REGN Stock Holding History

Gilbert & Cook’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,695
Closed -$1.31M – 237
2026
Q1 		$1.31M Sell
1,695
-14
-0.8% -$10.7K 0.17% 55
2025
Q4 		$1.32M Sell
1,709
-25
-1% -$17K 0.17% 60
2025
Q3 		$975K Sell
1,734
-3
-0.2% -$1.7K 0.13% 76
2025
Q2 		$912K Buy
1,737
+34
+2% +$19K 0.12% 77
2025
Q1 		$1.08M Buy
1,703
+3
+0.2% +$2.06K 0.16% 59
2024
Q4 		$1.21M Sell
1,700
-5
-0.3% -$4.2K 0.17% 58
2024
Q3 		$1.79M Sell
1,705
-45
-3% -$50.1K 0.25% 32
2024
Q2 		$1.84M Sell
1,750
-182
-9% -$176K 0.27% 27
2024
Q1 		$1.86M Buy
1,932
+25
+1% +$23.8K 0.25% 32
2023
Q4 		$1.67M Buy
1,907
+146
+8% +$120K 0.24% 32
2023
Q3 		$1.45M Buy
1,761
+1,182
+204% +$929K 0.23% 36
2023
Q2 		$416K Buy
+579
New +$446K 0.07% 135

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Gilbert & Cook's REGN Position: Q2 2026 in Review

Gilbert & Cook sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 1,695 shares — an estimated $1.31M sold.

Gilbert & Cook first reported a position in REGN in Q2 2023 and held it in 12 quarters. The position peaked at $1.86M in Q1 2024. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Gilbert & Cook reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Gilbert & Cook sold 1,695 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.31M.
  • Gilbert & Cook first reported a position in Regeneron Pharmaceuticals in Q2 2023 and held it in 12 quarters.
  • Gilbert & Cook's Regeneron Pharmaceuticals position peaked at $1.86M in Q1 2024.
  • 1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Gilbert & Cook's 13F filing for Q2 2026, filed 28 Jul 2026.